Key Takeaways

  • AI can now design entirely new viruses, moving beyond merely modifying existing ones, a milestone with both biotech potential and serious biosecurity questions.
  • This AI-driven method makes viral generation a thousand times cheaper, rapidly accelerating research but also lowering the barrier for misuse.
  • Initial experiments successfully created bacteriophages (viruses that infect bacteria), demonstrating the underlying capability, though the method's application is broader.
  • Despite the speed of scientific progress, governments and scientific organizations are critically slow in developing robust guardrails to prevent dangerous applications.
  • The lack of regulation means biotech founders are operating in a fast-moving, high-stakes environment where innovation outpaces safety protocols.

The AI-Driven Viral Revolution Is Here

For ambitious founders, the world just got a lot weirder – and faster. Scientists have successfully used AI to create entirely new viruses from scratch. This isn't just tweaking an existing strain; it's a leap forward. As John Coogan put it, "For the first time, scientists have used AI to create entirely new viruses… It's marked a milestone that could accelerate biotechnology while also raising long-term biocurity questions." Think about that: AI can now invent life, albeit viral life. The immediate impact? Cost. Coogan suggests that if “it becomes a thousand times cheaper to generate viruses, then that could… reshape biotech in a positive way, but also have biocurity implications.”

This dramatic drop in cost and increase in speed for viral generation changes everything. For biotech startups, it means faster prototyping, quicker iteration on gene therapies, and potentially unlocking treatments previously too expensive or complex. But for everyone else, it’s a flashing red light. The initial experiments focused on bacteriophages, viruses that infect bacteria. While not human pathogens, the underlying methodology is now proven. It’s a powerful new tool, and like any powerful tool, its use cases range from healing to harm.

The Unsettling Cost of Progress

When we talk about viruses, the "post-Wuhan era" looms large. The idea of AI-designed viruses in this context is unsettling for many. Jordi Hays reflected this unease, stating that the focus on bacteriophages "doesn't make me that comforted to be honest. You like your bacteria, you know, we naturally have… it's part of being human, right?" Her point is sharp: even bacterial viruses impact biological systems we rely on, highlighting the interconnectedness of biological risk. The ease and low cost of AI-driven viral generation fundamentally alters the biosecurity landscape. It means the ability to create complex biological agents is no longer limited to high-tech labs with massive budgets. The barrier to entry just plummeted.

Imagine the implications for gene therapies, which often use modified viruses to deliver genetic material. AI could design more efficient, targeted viral vectors, accelerating breakthroughs. But it also means the public perception of "virus" needs rebranding, fast. This dual nature—immense potential for good, terrifying potential for harm—is the central tension founders must grasp. Innovation always outpaces regulation, but with biological agents, that gap feels particularly dangerous.

The Guardrail Gap and Geopolitical Stakes

Perhaps the most pressing concern is the glaring absence of robust guardrails. Coogan explicitly states that “governments and scientific organizations have been slow to develop guard rails that could block the creation of a deadly virus even as the science races ahead.” This isn't just a regulatory oversight; it's a critical vulnerability. While the U.S. might debate regulating AI development, Samir Call from Coastal Ventures offers a counterpoint: “On the virus side, that's scary. And that gives a that's a perfect example of why we can't regulate our US companies in AI. We have to stay ahead and be at the cutting edge so we know how to protect ourselves.”

Call's argument introduces a geopolitical dimension: if the U.S. slows its own biotech AI development with regulations, other nations or rogue actors might not. This creates a race where knowing how to build is essential for knowing how to defend. For founders, this means operating in a wild west. The lack of clear ethical boundaries or enforcement mechanisms is a double-edged sword: freedom to innovate, but also potential liability and societal risk if things go wrong.

What to Do With This

If you're building in biotech, or even just investing, dedicate a weekly hour to biosecurity threat modeling. Specifically, identify five potential misuses of AI-generated viruses that could impact your sector or an adjacent one, then brainstorm immediate, practical preventative measures your team or portfolio companies could implement today, not in a year.